locoregionally advanced nasopharyngeal carcinoma

Induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin - A phase II study

D. Ferrari, F. Chiesa, C. Codecà, L. Calabrese, B. A. Jereczek-Fossa, D. Alterio, J. Fiore, A. Luciani, I. Floriani, R. Orecchia, P. Foa

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Chemoradiotherapy is the current standard of care for locoregionally advanced nasopharyngeal carcinoma. The purpose of this study was to assess the feasibility and efficacy of induction chemotherapy (CHT) followed by concomitant chemoradiotherapy in this patient population. Patients and Methods: In this single-arm, phase II study, patients with locoregionally advanced nasopharyngeal carcinoma were treated with 3 cycles of induction CHT with cisplatin (100 mg/m2 on day 1) and 5-fluorouracil (1,000 mg/m2 continuous infusion on days 1-4) followed by 3 cycles of cisplatin (100 mg/m2 on days 1, 22 and 43) and concurrent radiotherapy up to 70 Gy. The primary endpoint was objective response. Results: Thirty-four patients were enrolled, and all completed both induction treatment and subsequent chemoradiotherapy. Objective response rates were 79.4% (95% CI 62.1-91.3) and 85.3% (95% CI 68.9-95.0) after induction CHT and chemoradiation, respectively. Treatment was well tolerated and toxicity was manageable. At a median follow-up of 29 months, 3-year overall survival and progression-free survival rates are 80.0% (95% CI 0.64-0.95) and 54.0% (95% CI 0.36-0.73), respectively. Conclusions: Induction CHT with cisplatin and 5-fluorouracil followed by concomitant chemoradiotherapy is a feasible and active regimen for patients with stage IIB-IVB nasopharyngeal carcinoma. This regimen resulted in excellent locoregional disease control and overall survival.

Original languageEnglish
Pages (from-to)158-166
Number of pages9
JournalOncology
Volume74
Issue number3-4
DOIs
Publication statusPublished - Sep 2008

Fingerprint

Induction Chemotherapy
Fluorouracil
Cisplatin
Chemoradiotherapy
Radiotherapy
Survival
Standard of Care
Disease-Free Survival
Survival Rate
Nasopharyngeal carcinoma
Therapeutics
Population

Keywords

  • Chemoradiation
  • Cisplatin
  • Fluorouracil
  • Nasopharyngeal carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

locoregionally advanced nasopharyngeal carcinoma : Induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin - A phase II study. / Ferrari, D.; Chiesa, F.; Codecà, C.; Calabrese, L.; Jereczek-Fossa, B. A.; Alterio, D.; Fiore, J.; Luciani, A.; Floriani, I.; Orecchia, R.; Foa, P.

In: Oncology, Vol. 74, No. 3-4, 09.2008, p. 158-166.

Research output: Contribution to journalArticle

@article{58670ac09c17497a9227146722c3799c,
title = "locoregionally advanced nasopharyngeal carcinoma: Induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin - A phase II study",
abstract = "Background: Chemoradiotherapy is the current standard of care for locoregionally advanced nasopharyngeal carcinoma. The purpose of this study was to assess the feasibility and efficacy of induction chemotherapy (CHT) followed by concomitant chemoradiotherapy in this patient population. Patients and Methods: In this single-arm, phase II study, patients with locoregionally advanced nasopharyngeal carcinoma were treated with 3 cycles of induction CHT with cisplatin (100 mg/m2 on day 1) and 5-fluorouracil (1,000 mg/m2 continuous infusion on days 1-4) followed by 3 cycles of cisplatin (100 mg/m2 on days 1, 22 and 43) and concurrent radiotherapy up to 70 Gy. The primary endpoint was objective response. Results: Thirty-four patients were enrolled, and all completed both induction treatment and subsequent chemoradiotherapy. Objective response rates were 79.4{\%} (95{\%} CI 62.1-91.3) and 85.3{\%} (95{\%} CI 68.9-95.0) after induction CHT and chemoradiation, respectively. Treatment was well tolerated and toxicity was manageable. At a median follow-up of 29 months, 3-year overall survival and progression-free survival rates are 80.0{\%} (95{\%} CI 0.64-0.95) and 54.0{\%} (95{\%} CI 0.36-0.73), respectively. Conclusions: Induction CHT with cisplatin and 5-fluorouracil followed by concomitant chemoradiotherapy is a feasible and active regimen for patients with stage IIB-IVB nasopharyngeal carcinoma. This regimen resulted in excellent locoregional disease control and overall survival.",
keywords = "Chemoradiation, Cisplatin, Fluorouracil, Nasopharyngeal carcinoma",
author = "D. Ferrari and F. Chiesa and C. Codec{\`a} and L. Calabrese and Jereczek-Fossa, {B. A.} and D. Alterio and J. Fiore and A. Luciani and I. Floriani and R. Orecchia and P. Foa",
year = "2008",
month = "9",
doi = "10.1159/000151363",
language = "English",
volume = "74",
pages = "158--166",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3-4",

}

TY - JOUR

T1 - locoregionally advanced nasopharyngeal carcinoma

T2 - Induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin - A phase II study

AU - Ferrari, D.

AU - Chiesa, F.

AU - Codecà, C.

AU - Calabrese, L.

AU - Jereczek-Fossa, B. A.

AU - Alterio, D.

AU - Fiore, J.

AU - Luciani, A.

AU - Floriani, I.

AU - Orecchia, R.

AU - Foa, P.

PY - 2008/9

Y1 - 2008/9

N2 - Background: Chemoradiotherapy is the current standard of care for locoregionally advanced nasopharyngeal carcinoma. The purpose of this study was to assess the feasibility and efficacy of induction chemotherapy (CHT) followed by concomitant chemoradiotherapy in this patient population. Patients and Methods: In this single-arm, phase II study, patients with locoregionally advanced nasopharyngeal carcinoma were treated with 3 cycles of induction CHT with cisplatin (100 mg/m2 on day 1) and 5-fluorouracil (1,000 mg/m2 continuous infusion on days 1-4) followed by 3 cycles of cisplatin (100 mg/m2 on days 1, 22 and 43) and concurrent radiotherapy up to 70 Gy. The primary endpoint was objective response. Results: Thirty-four patients were enrolled, and all completed both induction treatment and subsequent chemoradiotherapy. Objective response rates were 79.4% (95% CI 62.1-91.3) and 85.3% (95% CI 68.9-95.0) after induction CHT and chemoradiation, respectively. Treatment was well tolerated and toxicity was manageable. At a median follow-up of 29 months, 3-year overall survival and progression-free survival rates are 80.0% (95% CI 0.64-0.95) and 54.0% (95% CI 0.36-0.73), respectively. Conclusions: Induction CHT with cisplatin and 5-fluorouracil followed by concomitant chemoradiotherapy is a feasible and active regimen for patients with stage IIB-IVB nasopharyngeal carcinoma. This regimen resulted in excellent locoregional disease control and overall survival.

AB - Background: Chemoradiotherapy is the current standard of care for locoregionally advanced nasopharyngeal carcinoma. The purpose of this study was to assess the feasibility and efficacy of induction chemotherapy (CHT) followed by concomitant chemoradiotherapy in this patient population. Patients and Methods: In this single-arm, phase II study, patients with locoregionally advanced nasopharyngeal carcinoma were treated with 3 cycles of induction CHT with cisplatin (100 mg/m2 on day 1) and 5-fluorouracil (1,000 mg/m2 continuous infusion on days 1-4) followed by 3 cycles of cisplatin (100 mg/m2 on days 1, 22 and 43) and concurrent radiotherapy up to 70 Gy. The primary endpoint was objective response. Results: Thirty-four patients were enrolled, and all completed both induction treatment and subsequent chemoradiotherapy. Objective response rates were 79.4% (95% CI 62.1-91.3) and 85.3% (95% CI 68.9-95.0) after induction CHT and chemoradiation, respectively. Treatment was well tolerated and toxicity was manageable. At a median follow-up of 29 months, 3-year overall survival and progression-free survival rates are 80.0% (95% CI 0.64-0.95) and 54.0% (95% CI 0.36-0.73), respectively. Conclusions: Induction CHT with cisplatin and 5-fluorouracil followed by concomitant chemoradiotherapy is a feasible and active regimen for patients with stage IIB-IVB nasopharyngeal carcinoma. This regimen resulted in excellent locoregional disease control and overall survival.

KW - Chemoradiation

KW - Cisplatin

KW - Fluorouracil

KW - Nasopharyngeal carcinoma

UR - http://www.scopus.com/inward/record.url?scp=49549101365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49549101365&partnerID=8YFLogxK

U2 - 10.1159/000151363

DO - 10.1159/000151363

M3 - Article

VL - 74

SP - 158

EP - 166

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3-4

ER -